The Most Rigorous Meta-Analysis of Cannabis for Chronic Pain Shows Real but Modest Benefits

The Numbers

Wang's team searched for every randomized controlled trial comparing medical cannabis or cannabinoids to placebo for chronic pain — both cancer and non-cancer. They found 32 trials spanning one to five and a half months of follow-up. Then they did something unusual for cannabis research: they applied GRADE methodology, the gold standard for rating the certainty of medical evidence.

That number needed to treat (NNT) deserves context. An NNT of 24 means you need to give cannabis to 24 chronic pain patients before one achieves meaningful relief beyond what a sugar pill provides. For comparison:

What Improved — and What Didn't

Wang's analysis broke outcomes into specific domains. The pattern was consistent: small improvements in pain, physical function, and sleep. No improvement in emotional, role, or social functioning.

The Side Effect Profile

The trade-off picture was equally specific. Cannabis isn't dangerous for most people in these trials, but it isn't side-effect-free either.

The dizziness finding at longer durations (28% increase over placebo at three months or more) is notable. Most cannabis-for-pain discussions focus on the short-term safety profile. This review showed that some side effects worsen, not improve, with continued use — the opposite of what tolerance-based arguments would predict.

Why The Results Seem Worse Than What Patients Report

There's a disconnect between these modest trial results and the enthusiastic reports from millions of cannabis users who say it helps their pain. Several factors explain the gap:

What This Means for Patients

The Bigger Picture

Wang's review appeared alongside a companion clinical practice guideline (Busse et al., 2021) in the same issue of the BMJ. The guideline recommended — with weak certainty — offering a trial of non-inhaled medical cannabis for chronic pain when standard care is insufficient. "Weak recommendation" isn't an insult. It means the evidence exists, the benefit-risk balance is plausible, but patient values and individual circumstances should drive the decision.

This is a meaningful shift from Whiting's 2015 JAMA review, which found moderate-quality evidence for chronic pain but fewer trials and less rigorous grading. Six years later, the evidence base had grown from 8 to 32 trials for pain — but the effect sizes hadn't grown with it. More data confirmed a small benefit, not a hidden large one.

For the millions living with chronic pain conditions who are considering cannabis, this study provides the most honest assessment available: real effects, modest magnitude, manageable side effects, and an evidence base that — while growing — still lags behind what patients deserve.

Frequently Asked Questions

Does cannabis work for chronic pain?

Yes, but modestly. The most rigorous evidence (32 randomized trials, 5,174 patients) shows cannabis produces a small but real improvement in pain intensity — about 10% more patients achieve meaningful relief compared to placebo. It also provides small improvements in sleep and physical function. However, it does not improve emotional or social functioning, and most individual patients in trials don't achieve clinically meaningful pain reduction beyond placebo. It's a genuine therapeutic option, not a miracle cure.

How does cannabis compare to other pain medications?

The number needed to treat (~24) is worse than acute pain treatments like NSAIDs (NNT ~3) or opioids for short-term pain (NNT ~4). But it's comparable to many medications used for chronic pain, and cannabis has a better long-term safety profile than opioids. For patients who've failed multiple conventional treatments, a modest benefit with manageable side effects can be clinically meaningful.

Why do patients report better results than the trials show?

Several factors: chronic pain trials have large placebo responses (~25% improvement), trial participants differ from self-selected cannabis users, most trials used pharmaceutical preparations rather than inhaled whole-plant cannabis, real-world patients can titrate their dose, and cannabis may help with pain-adjacent symptoms (anxiety, sleep, quality of life) that trial endpoints don't fully capture.

What are the main side effects?

Dizziness (9-28% above placebo), drowsiness (5%), nausea (5%), impaired attention (3%), and cognitive impairment (2%). Notably, dizziness worsened at longer treatment durations. Most side effects were self-limiting and not serious. No increase in serious adverse events was found compared to placebo.